News & Updates

Patients with chronic myeloid leukaemia (CML) who are being treated with both tyrosine kinase inhibitors (TKIs) and selective serotonin reuptake inhibitors (SSRIs) do not appear to be at greater total risk of bleeding or thrombotic events than those on TKIs only, reveals a study. However, concomitant use of TKIs and SSRIs may elevate the risk of intracranial bleeding.

Using hydrochlorothiazide (HCTZ) for longer durations and in higher cumulative doses increases the risks for keratinocyte carcinoma and melanoma, reveals a study.

In the treatment of ERBB2-positive metastatic breast cancer (MBC), the use of pertuzumab plus trastuzumab alone in the first-line setting and delaying chemotherapy may be a reasonable option for some patients, with the treatment strategy not compromising overall survival (OS) despite a much shorter progression-free survival (PFS), as shown in a study.

Treatment with S-1, an oral fluoropyrimidine formulation similar to capecitabine, plus oxaliplatin (SOX) results in substantial improvements in overall response rate relative to capecitabine plus oxaliplatin (CapeOx) in patients with metastatic colorectal cancer, according to a Philippines study presented at the recent ESMO GI 2023.

Individuals with metabolic syndrome (MetS) have a heightened risk of incident lung cancer, with the risk increase especially pronounced in those with a higher number of metabolic abnormalities and in women, according to a study.

Seventy percent of patients with metastatic hormone-sensitive prostate cancer (mHSPC) experience disease-related complications, while 59 percent require ≥1 unplanned hospital admission during the course of disease, a study by the Chinese University of Hong Kong (CUHK) has shown.